Antibody drugs for the treatment of stroke have attracted considerable attention from the scientific community. There is growing evidence that targeting endogenous molecules or signaling cascades with monoclonal antibodies can reduce the severity of injury or completely heal damaged brain tissue. Antibody-based therapies offer a novel adjunct to stroke treatment. Many molecules have been targeted for stroke therapy and many antibodies have been developed. These molecules are primarily located on cell membranes or in the extracellular space, where they can be targeted by antibodies.
Fig. 1. Schematic representative diagram demonstrating intravenous or subcutaneous injection of different forms of antibody-based medications to a stroke patient. (Sun et al., 2022)
As a CRO service provider focused on stroke, Ace Therapeutics helps clients develop safe and effective therapeutic antibodies. Our comprehensive services cover the full spectrum of therapeutic antibody development, from initial target identification and antibody discovery to preclinical evaluation.
Using our extensive expertise in hybridoma technology, phage display and single-cell sequencing, we help clients to generate a broad range of high-affinity, specific antibodies that selectively modulate key molecular pathways involved in stroke pathogenesis.
Ace Therapeutics identifies and validates multiple molecules as targets and provides one-stop therapeutic antibody development services for stroke.
Strategies | Service Details |
Custom Antibody Engineering | Our skilled engineers use advanced techniques such as Fc engineering and antibody humanization to fine-tune the structural and functional characteristics of therapeutic antibodies. We can extend their half-life, improve BBB permeability, and enhance their ability to trigger desired biological responses in the ischemic brain microenvironment. |
Cell Receptor-mediated Strategies | We make antibodies reach the brain using cellular receptor-mediated strategies. This strategy utilizes certain BBB enriched receptors, such as transferrin receptor (TfR), insulin receptor (IR), and diphtheria toxin receptor (DTR), which can be potentially conjugated to increase the ability of receptor-mediated transport of antibodies into the brain. |
Antibody-Drug Conjugates | We modify the surface of drug-carrying nanoparticles by binding them to brain-specific antibodies. These antibody-drug conjugates recognize specific ligands and act as stroke therapeutics through receptor-mediated endocytosis across the BBB. |
Single-domain Antibodies | We develop single-domain antibodies to be used as carriers for the transport of antibodies across the BBB. In addition, we develop therapeutic single-domain antibodies that improve the BBB and tissue permeability and contribute to surface modifications for site-specific targeting. |
Ace Therapeutics aims to help clients accelerate the development of therapeutic antibodies for stroke. Our team collaborates with academic and pharmaceutical partners to design and execute well-controlled preclinical studies. Please fell free to contact us. We look forward to working with you!
We are committed to accelerating progress in stroke research and drug development.